Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Human Vaccines & Immunotherapeutics|May 15, 2023
Kymriah® (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapyRakesh Awasthi, Harald J Maier, Jie Zhang, et al.
Journal of Pharmaceutical Sciences|September 25, 2017
Relating Observed Psychoactive Effects to the Plasma Concentrations of Delta-9-Tetrahydrocannabinol and Its Active Metabolite: An Effect-Compartment Modeling ApproachRakesh Awasthi, Guohua An, Maureen D Donovan, et al.
Journal of Pharmaceutical Sciences|August 11, 2016
A Physiologically Based Pharmacokinetic Model to Describe Artemether Pharmacokinetics in Adult and Pediatric PatientsWen Lin, Tycho Heimbach, Jay Prakash Jain, et al.
Blood Advances|January 26, 2021
Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapyJochen Buechner, Stephan A Grupp, Hidefumi Hiramatsu, et al.
Blood Neoplasia|January 15, 2026
Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomasJulio C Chavez, Ellen Napier, Attilio Bondanza, et al.
Blood|September 23, 2017
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemiaKaren Thudium Mueller, Shannon L Maude, David L Porter, et al.
Blood Advances|July 24, 2019
Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusionMichael R Bishop, Richard T Maziarz, Edmund K Waller, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 9, 2019
Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T CellsAndrew M Stein, Stephan A Grupp, John E Levine, et al.
Journal for Immunotherapy of Cancer|April 13, 2026
Data-informed optimization of CAR T-cell therapy long-term follow-upBetsy Foss-Campbell, Nancy Myers, Rakesh Awasthi, et al.
Blood Advances|June 24, 2025
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCLRakesh Awasthi, Stephan A Grupp, Edward R Waldron, et al.
Pageof 2